"","Num","POD","SD","%","Genes","KE"
"ABNORMAL RENAL TUBULE MORPHOLOGY","1","0.00139509080242197",NA,"11.11","553672","OCCURRENCE CYSTIC DILATATION RENAL TUBULE; OCCURRENCE CYTOPLASMIC VACUOLIZATION RENAL TUBULE"
"RENAL TUBULAR DYSFUNCTION","1","0.00139509080242197",NA,"3.85","553672","INCREASE HYPERPLASIA RENAL TUBULAR CELLS; INCREASE CYTOTOXICITY RENAL TUBULAR CELL; INCREASE ADENOMAS/CARCINOMAS RENAL TUBULAR; OCCURRENCE RENAL PROXIMAL TUBULAR NECROSIS"
"VENTRICULAR ARRHYTHMIA","1","0.00139509080242197",NA,"14.29","553672","OCCURRENCE CARDIAC ARRHYTHMIA"
"ABNORMAL SOCIAL BEHAVIOR","2","0.00240031349905226","0.166640667521457","7.69","553672, 402966","ABNORMAL FORAGING ACTIVITY AND BEHAVIOR"
"ABNORMAL THYROID HORMONE LEVEL","1","0.00412984221796185",NA,"5","402966","INCREASED HEPATIC THYROID HORMONE UPTAKE/TRANSPORT; DECREASE SERUM THYROID HORMONE T4/T3; DECREASED THYROXINE T4 IN SERUM; DECREASED THYROXINE T4 IN TISSUES; DECREASED TRIIODOTHYRONINE T3 IN TISSUES; INCREASED TRIIODOTHYRONINE T3 IN TISSUES"
"INCREASED SERUM SEROTONIN","1","0.00412984221796185",NA,"33.33","402966","INCREASED SERUM CREATININE"
"TUBE FEEDING","1","0.00412984221796185",NA,"5.88","402966","INHIBITION FEEDING"
"GO:0044414","1","0.00575862434723579",NA,"2.5","57934","SUPPRESSION IMMUNE SYSTEM"
"FAS LIGAND FASL PATHWAY AND STRESS INDUCTION OF HEAT SHOCK PROTEINS HSP REGULATION","1","0.00575862434723579",NA,"3.85","57934","ACTIVATION FAS; UP REGULATION FAS"
"PROGRESSIVE HEARING IMPAIRMENT","1","0.00575862434723579",NA,"12.5","57934","REDUCED HEARING; REDUCED HEARING"
"YOUNG ADULT ONSET","1","0.00575862434723579",NA,"33.33","57934","REDUCED YOUNG OF YEAR SURVIVAL"
"ABNORMALITY OF ADRENAL PHYSIOLOGY","2","0.00577184085276249","0.102799811873398","2.17","30483, 402966","INCREASE RENAL PATHOLOGY DUE TO VTG DEPOSITION; DECREASED RENAL ABILITY TO DILUTE URINE; OCCURRENCE KIDNEY TOXICITY; INCREASED KIDNEY FAILURE"
"ABNORMAL LUNG MORPHOLOGY","2","0.00577184085276249","0.102799811873398","1.56","30483, 402966","INCREASE ADENOMAS/CARCINOMAS BRONCHIOLOALVEOLAR"
"TISSUE ISCHEMIA","2","0.00681564548402822","0.0517519032236946","13.33","57934, 30483","OCCURRENCE RENAL ISCHEMIA"
"GO:0006954","1","0.00766001239798177",NA,"0.85","560100","INCREASE INFLAMMATION; INCREASE INFLAMMATION CORNEAL CELLS; INFILTRATION INFLAMMATORY CELLS; INCREASED INFLAMMATION; CHRONIC COUGH RESPIRATORY IRRITABILITY"
"GO:0007269","1","0.00766001239798177",NA,"4","560100","OVERACTIVATION NEURONOTRANSMITTER RELEASE"
"GO:0007588","1","0.00766001239798177",NA,"7.14","560100","INCREASE BILIARY EXCRETION TH GLUCURONIDE"
"GO:0042311","1","0.00766001239798177",NA,"6.67","560100","IMPAIRED VASODILATION"
"GO:0044557","1","0.00766001239798177",NA,"33.33","560100","RELAXATION SMOOTH MUSCLE"
"JNK CASCADE","1","0.00766001239798177",NA,"4.55","560100","ACTIVATION JNK"
"ABNORMALITY OF THE MITOCHONDRION","2","0.00771229899884528","0.525084331448826","1.59","554101, 553672","INJURY MITOCHONDRIA; DAMAGING MITOCHONDRIA; N/A MITOCHONDRIAL DYSFUNCTION 1"
"ABNORMAL CARDIAC TEST","1","0.00806668755642174",NA,"7.69","30483","INCREASED CARDIAC ARRTHYMIA"
"ABNORMAL CIRCULATING ESTROGEN LEVEL","1","0.00806668755642174",NA,"7.14","30483","INCREASED CIRCULATING ESTROGEN LEVELS"
"ABNORMAL OVARIAN MORPHOLOGY","1","0.00806668755642174",NA,"2.7","30483","PROMOTION OVARIAN GRANULAR CELL TUMORS; DECREASED OVARIAN E2; PROMOTION OVARIAN ADENOMAS"
"ABNORMALITY OF THE OVARY","1","0.00806668755642174",NA,"1.75","30483","REDUCED PROSTAGLANDINS OVARY"
"CYANOSIS","1","0.00806668755642174",NA,"5.26","30483","N/A CYANOSIS OCCURS"
"INCREASED PULMONARY VASCULAR RESISTANCE","1","0.00806668755642174",NA,"25","30483","INCREASE VASCULAR RESISTANCE"
"MALE REPRODUCTIVE SYSTEM NEOPLASM","1","0.00806668755642174",NA,"6.67","30483","MALFORMATION MALE REPRODUCTIVE TRACT; INDUCTION MALE REPRODUCTIVE TRACT; MALFORMED MALE REPRODUCTIVE TRACT"
"GO:0006120","2","0.00816483894453899","0.542594956943564","7.41","325712, 553672","BINDING OF INHIBITOR NADH-UBIQUINONE OXIDOREDUCTASE COMPLEX I"
"GO:0006936","3","0.00985219397257632","0.0567447551164532","5.45","560100, 796865, 30483","REDUCTION ABDOMINAL MUSCLE CONTRACTION; OVERACTIVATION MUSCLE CONTRACTION"
"GO:0046983","2","0.0100120913596236","0.301284951830763","1.02","553610, 192330","DIMERIZATION AHR/ARNT; REDUCED DIMERIZATION ARNT/HIF1-ALPHA"
"UPPER MOTOR NEURON DYSFUNCTION","3","0.0101124660172061","0.261450141271968","0.63","406468, 796865, 553672","DECREASE HISTAMINERGIC NEURON EXCITATION; OCCURRENCE CYTOPLASMIC VACUOLIZATION BILE DUCT CELL; OCCURRENCE CYTOPLASMIC VACUOLIZATION KUPFFER CELL"
"ABNORMALITY OF THE PITUITARY GLAND","3","0.0101610706444446","0.149863161964677","6.25","30126, 30483, 402966","INCREASED ADENOMAS PITUITARY"
"DECREASED FERTILITY","3","0.0101610706444446","0.149863161964677","3.95","30126, 30483, 402966","IMPAIRED FERTILITY; DECREASED SPERM QUANTITY OR QUALITY IN THE ADULT DECREASED FERTILITY; REDUCTION CUMULATIVE FECUNDITY AND SPAWNING; DECREASED SPERM QUANTITY OR QUALITY IN THE ADULT DECREASED FERTILITY; DECREASED SPERM QUANTITY OR QUALITY IN THE ADULT DECREASED FERTILITY; DECREASED TESTOSTERONE"
"GO:0019932","2","0.0111021857692028","0.113970776195253","3.28","560100, 554230","INCREASED SECOND MESSENGER PRODUCTION"
"GO:0072358","2","0.0113930858953756","0.106027929382744","1.8","30483, 554230","ALTERED CARDIOVASCULAR DEVELOPMENT/FUNCTION"
"HYPERACTIVITY","4","0.0125357222601398","0.113326291556429","8","406468, 796865, 30483, 402966","INDUCTION ATAXIA PARALYSIS OR HYPERACTIVITY; INCREASED ATAXIA PARALYSIS OR HYPERACTIVITY; N/A ATAXIA PARALYSIS OR HYPERACTIVITY"
"GO:0019882","2","0.0129617728208885","0.348124661792863","3.39","415202, 415221","GENERATION OF NOVEL EPITOPES  ANTIGEN PRESENTATION"
"GO:1903009","2","0.0129617728208885","0.348124661792863","5.88","415202, 415221","DECREASE GTPCH-1"
"CTOME CELLULAR RESPONSE TO HYPOXIA","2","0.0129617728208885","0.348124661792863","4.65","415202, 415221","N/A HYPOXIA"
"MORTALITY AGING","2","0.0132693408654961","0.35844366392737","7.69","554101, 402966","REDUCED FITNESS OR EVEN MORTALITY ACIDOSIS HYPOVOLEMIC SHOCK AND ORGAN DYSFUNCTION; INCREASE MORTALITY; INCREASED MORTALITY"
"ABNORMAL RESPIRATORY SYSTEM MORPHOLOGY","3","0.0133876603420392","0.216452688967095","2.04","30483, 326961, 402966","INCREASED RESPIRATORY DISTRESS/ARREST"
"GO:0045333","3","0.0141651168721875","0.290702715511496","4.17","554101, 325712, 553672","INCREASE OXIDATIVE METABOLISM"
"ABNORMALITY OF REPRODUCTIVE SYSTEM PHYSIOLOGY","4","0.0149719460121491","0.124525495750511","3.88","406468, 30126, 30483, 402966","N/A IMPAIRMENT OF REPRODUCTIVE CAPACITY"
"GO:0044703","1","0.0154765499167321",NA,"0.86","796865","N/A REPRODUCTIVE FAILURE"
"GO:0001525","1","0.0160911657122598",NA,"2.7","554230","REDUCTION ANGIOGENESIS; INCREASED ANGIOGENESIS"
"GO:0001935","1","0.0160911657122598",NA,"2.78","554230","INCREASED PROLIFERATION ENDOTHELIAL CELLS"
"GO:0003158","1","0.0160911657122598",NA,"4.17","554230","IMPAIRMENT ENDOTHELIAL NETWORK"
"GO:0016310","1","0.0160911657122598",NA,"0.8","554230","ACTIVATION SP1"
"GO:0043542","1","0.0160911657122598",NA,"2.86","554230","INCREASED MIGRATION ENDOTHELIAL CELLS"
"GO:0048870","1","0.0160911657122598",NA,"0.5","554230","INCREASED MOTILITY"
"GO:0051899","1","0.0160911657122598",NA,"4.76","554230","OCCURRENCE A PAROXYSMAL DEPOLARIZING SHIFT; PROLONGED DEPOLARIZATION OF NEURONAL MEMBRANE"
"GO:1904019","1","0.0160911657122598",NA,"4.55","554230","DECREASE APOPTOSIS OF CILIATED EPITHELIAL CELLS"
"CTOME VEGFR2 MEDIATED CELL PROLIFERATION","1","0.0160911657122598",NA,"16.67","554230","INHIBITION VEGFR2"
"G VEGF SIGNALING PATHWAY","1","0.0160911657122598",NA,"4.76","554230","REDUCED PRODUCTION VEGF"
"GO:0000003","3","0.0165033181020983","0.108573939823186","1.48","30541, 796865, 30483","REDUCED REPRODUCTIVE SUCCESS; REPRODUCTIVE FAILURE"
"DECREASED BODY WEIGHT","9","0.0167151011794952","0.0691443303754726","3.98","57934, 554101, 406408, 406468, 30483, 553672, 325618, 326961, 402966","DECREASED BODY WEIGHT"
"GO:0005515","2","0.0176755026731789","0.0288388311691449","4.26","30482, 554230","BINDING SH-/SELEN-PROTEINS; COVALENT BINDING PROTEIN"
"ABNORMAL NASAL MORPHOLOGY","8","0.0181030859101659","0.0573481783166288","5.16","57934, 406468, 30483, 30482, 325618, 326961, 100000341, 402966","INCREASE SITE OF CONTACT NASAL TUMORS"
"GO:0046903","6","0.0190505646576734","0.0631029088635975","2.6","560100, 406408, 30126, 373081, 394000, 100331439","SUPPRESSION VLDL SECRETION; INCREASE MUCIN PRODUCTION; INCREASED SECRETION OF LOCAL GROWTH FACTORS"
"GO:0010468","1","0.0194158335285505",NA,"6.25","30482","DECREASED TRANSCRIPTION OF GENES BY AR"
"VASCULAR CALCIFICATION","1","0.0194158335285505",NA,"20","30482","OSTEOPOROSIS AND VASCULAR CALCIFICATION BONE DETERIORATION"
"GO:0005488","21","0.0223482545757741","0.0321008626006015","1.95","57934, 619259, 30541, 30126, 30483, 30482, 553575, 554230, 325712, 553672, 394000, 553610, 140620, 415202, 415227, 326961, 336662, 402966, 192330, 447922, 60632","INCREASED BINDING OF CHEMICALS TO 2U SERUM"
"GO:0006412","5","0.0225444336057553","0.0801094386899971","4.63","325618, 326961, 394166, 100000341, 336662","ALTERED PROTEIN PRODUCTION"
"ABNORMAL LIVER MORPHOLOGY","5","0.022793248194479","0.13645733635349","4.2","554101, 406408, 406468, 553672, 394000","INDUCTION LIVER “DYSFUNCTIONAL” CHANGES BY CGA 330050; INFLAMMATION LIVER; N/A LIVER FIBROSIS; INCREASE RBC CONGESTION IN LIVER; INCREASE LIVER AND SPLENIC HEMOSIDEROSIS; REDUCTION VITELLOGENIN SYNTHESIS IN LIVER; INCREASE VITELLOGENIN SYNTHESIS IN LIVER; FORMATION LIVER FIBROSIS; FORMATION LIVER TUMOR"
"ABNORMALITY OF THE ABDOMINAL ORGANS","5","0.022793248194479","0.13645733635349","2.96","554101, 406408, 406468, 553672, 394000","IMPAIRED DEVELOPMENT OF REPRODUCTIVE ORGANS"
"ABNORMALITY OF THE LIVER","5","0.022793248194479","0.13645733635349","0.67","554101, 406408, 406468, 553672, 394000","INCREASED INDUCTION OF UDPGT'S IN LIVER; INCREASED LIVER STEATOSIS; INCREASED LIVER STEATOSIS; N/A HEPATOTOXICITY HEPATOPATHY INCLUDING A CONSTELLATION OF OBSERVABLE EFFECTS; INDUCTION SUSTAINED HEPATOTOXICITY"
"GO:0030163","3","0.0229582117447842","0.217894209476886","1.96","415202, 415221, 326961","INCREASED CATABOLISM OF MUSCLE PROTEIN"
"GO:0030154","3","0.0263253335555367","0.0624712851059138","4.62","30541, 30126, 554230","DIFFERENTIATION OF MYOFIBROBLAST"
"CYTOPLASMIC RIBOSOMAL PROTEINS","4","0.0264801687304766","0.106466344594267","2.78","325618, 326961, 394166, 100000341","OCCURRENCE CYTOPLASMIC VACUOLIZATION PODOCYTE"
"GO:0009611","5","0.0286249966128972","0.164454944612141","4.46","57934, 30126, 30483, 30482, 60632","ACCUMULATION DAMAGED MITOCHONDRIAL DNA"
"GO:0042060","5","0.0286249966128972","0.164454944612141","5.68","57934, 30126, 30483, 30482, 60632","FAILURE IN VASCULAR REPAIR MECHANISMS UNRESOLVED BLOOD LOSS HEMORRHAGE"
"GO:0001775","6","0.0301150371119791","0.128253055361878","3.06","57934, 560100, 406408, 373081, 394000, 60632","ACTIVATION DENDRITIC CELLS"
"ABNORMAL PROLACTIN LEVEL","1","0.031491236742484",NA,"12.5","30126","DECREASED PROLACTIN"
"ANTERIOR PITUITARY AGENESIS","1","0.031491236742484",NA,"20","30126","INCREASED SECRETION OF LH FROM ANTERIOR PITUITARY"
"LOCOMOTORY BEHAVIOR","1","0.031491236742484",NA,"1.61","30126","REDUCED SWIMMING SPEED; REDUCED SWIMMING PERFORMANCE"
"ELECTRON TRANSPORT CHAIN","5","0.0335344830939178","0.187972706688991","7.35","554101, 554103, 553575, 325712, 553672","DISRUPTION MITOCHONDRIAL ELECTRON TRANSPORT CHAIN"
"GO:0009653","2","0.0336718571475487","0.0205607937775576","40","30541, 30126","INCREASED DEVELOPMENTAL DEFECTS"
"POSITIVE REGULATION OF GENE EXPRESSION","5","0.0337757166566088","0.168451745666238","2.76","57934, 30483, 30482, 326961, 60632","ALTERED GENE EXPRESSION"
"GO:0099536","3","0.0345101399379854","0.373098127493414","2.7","560100, 100331439, 60632","DECREASED NEURONAL NETWORK FUNCTION IN ADULT BRAIN; DECREASED NEURONAL NETWORK FUNCTION IN ADULT BRAIN"
"GO:0001816","3","0.034708091116953","0.372391489131205","2.5","560100, 30483, 60632","NON-NEURONAL PRODUCTION OF TNF EPITHELIAL IRRITATION; PRODUCTION OF NERVE GROWTH FACTOR  EPITHELIAL IRRITATION; NON-NEURONAL PRODUCTION OF IL-8/CXCL1 EPITHELIAL IRRITATION"
"GO:0030520","1","0.0360034752854071",NA,"12.5","30541","ACTIVATION ESTROGEN RECEPTOR ALPHA"
"GO:0048469","1","0.0360034752854071",NA,"4.17","30541","INCREASED OOCYTE MATURATION"
"STEROID HORMONE MEDIATED SIGNALING PATHWAY","1","0.0360034752854071",NA,"0.98","30541","DECREASE STEROIDOGENIC ACUTE REGULATORY PROTEIN STAR; DECREASED HSD17B10 EXPRESSION; REDUCED MATURATION INDUCING STEROID PLASMA"
"RESPONSE TO ESTRADIOL","1","0.0360034752854071",NA,"3.33","30541","REDUCTION PLASMA 17BETA-ESTRADIOL CONCENTRATIONS"
"GO:0046562","1","0.0367440410095609",NA,"3.7","394000","DECREASED GLUCOSE OXIDASE ENZYME ACTIVITY"
"PYRUVATE METABOLIC PROCESS","1","0.0367440410095609",NA,"1.79","394000","INHIBITION 4-HYDROXYPHENYL-PYRUVATE DIOXYGENASE HPPD ENZYME"
"GO:0009790","5","0.0397774439461773","0.147021069937461","2.96","30541, 30126, 30483, 554230, 60632","DEFECT OF EMBRYOGENESIS"
"REGULATION OF CELL DEATH","4","0.0421695203565502","0.21157421342952","1.49","30541, 30483, 554230, 60632","N/A CELL INJURY/DEATH"
"ABNORMALITY OF BLOOD AND BLOOD FORMING TISSUES","6","0.0423394235116164","0.141520759473428","1.49","406408, 553575, 553672, 394000, 325618, 326961","DAMAGING RED BLOOD CELLS; HEMOLYSIS"
"HEART DEVELOPMENT","4","0.042741732079959","0.209079341204095","3.17","30126, 30483, 30482, 60632","ALTERED LARVAL DEVELOPMENT; IMPAIRED DEVELOPMENT"
"GO:0004872","3","0.0436912851509537","0.347691573455439","1.26","560100, 554230, 60632","ACTIVATION PXR/SXR"
"LIPID ACCUMULATION IN HEPATOCYTES","2","0.0464712539964917","0.0721231060028524","6.25","406408, 394000","INCREASE PRENEOPLASTIC FOCI HEPATOCYTES"
"GO:0006633","1","0.0477851297381693",NA,"3.45","325712","SYNTHESIS DE NOVO FA; INCREASED DE NOVO FA SYNTHESIS; INCREASED DE NOVO FA SYNTHESIS"
"PEPTIDYL LYSINE MODIFICATION","1","0.0477851297381693",NA,"1.41","325712","N/A COVALENT BINDING TO PROTEIN POSSIBLY LYSINE RESIDUE"
"GO:0006629","2","0.0478402767542846","0.000354199612445815","0.97","406468, 325712","ALTERATION LIPID METABOLISM"
"REGULATION OF WNT SIGNALING PATHWAY","3","0.0484431188880192","0.369065312269507","3.8","415202, 415221, 60632","INHIBITION WNT PATHWAY"
"ELEVATED RED CELL ADENOSINE DEAMINASE LEVEL","2","0.0563111934105697","0.0755830886314675","11.11","325618, 326961","INCREASED CYCLIC ADENOSINE MONOPHOSPHATE"
"PURE RED CELL APLASIA","2","0.0563111934105697","0.0755830886314675","10","325618, 326961","N/A METHEMOGLOBINEMIA DECREASED HEMOGLOBIN HEMATOCRIT RED BLOOD CELL NUMBER"
"GO:0019904","3","0.0915448406227922","0.250969022047608","2.44","30541, 30126, 60632","N/A INTERFERENCES WITH SH-/SELEN-PROTEINS"
"GO:0005102","2","0.104346405408863","0.574092914278802","0.96","554230, 60632","DECREASED TESTOSTERONE BINDING TO ANDROGEN RECEPTOR HYPOTHALAMUS"
"GO:0040011","2","0.104346405408863","0.574092914278802","0.88","554230, 60632","INCREASED LOCOMOTION; INCREASED MUSCULAR WAVES IN FOOT; DECREASED LOCOMOTION"
"GO:0050673","2","0.104346405408863","0.574092914278802","2.44","554230, 60632","INCREASE REGENERATIVE CELL PROLIFERATION TUBULAR EPITHELIAL CELLS; INCREASE REGENERATIVE CELL PROLIFERATION TERMINAL BRONCHIOLAR EPITHELIAL CELLS"
"REGULATION OF PROTEOLYSIS","2","0.220763067212187","0.343965771365788","1.79","326961, 60632","IMPAIRED PROTEOSTASIS"
"GO:0016209","1","0.602988348612224",NA,"9.09","553575","OXIDATION GLUTATHIONE"
"NRF2 PATHWAY","1","0.602988348612224",NA,"2.5","553575","ACTIVATION NRF2"
"OXIDATIVE STRESS","1","0.602988348612224",NA,"4.17","553575","PROPAGATION OXIDATIVE STRESS; N/A OXIDATIVE STRESS; INCREASE OXIDATIVE STRESS / ACTIVATION PMK-1 P38 MAPK; INCREASED OXIDATIVE STRESS; INCREASE OXIDATIVE STRESS / ACTIVATION PMK-1 P38 MAPK; INCREASE ENERGETIC DEMANDS AND THEREFORE METABOLIC STRESS; INCREASED ENERGETIC DEMANDS AND THEREFORE METABOLIC STRESS"
"GLUTATHIONE METABOLIC PROCESS","1","0.602988348612224",NA,"10","553575","GLUTATHIONE SYNTHESIS; GLUTATHIONE HOMEOSTASIS"
"G GLUTATHIONE METABOLISM","1","0.602988348612224",NA,"12.5","553575","DEPLETION GSH"
"GO:0006898","1","0.67665528504595",NA,"2.63","60632","REDUCTION VITELLOGENIN ACCUMULATION INTO OOCYTES AND OOCYTE GROWTH/DEVELOPMENT; INCREASED LDL UPTAKE"
"GO:0016055","1","0.67665528504595",NA,"4.35","60632","ALTERATION WNT PATHWAY"
"GO:0030545","1","0.67665528504595",NA,"1.69","60632","DESENSITIZATION NICOTINIC ACETYLCHOLINE RECEPTOR"
"GO:0045444","1","0.67665528504595",NA,"2.44","60632","INCREASED ADIPOGENESIS"
"BREAST CANCER PATHWAY","1","0.67665528504595",NA,"0.88","60632","N/A BREAST CANCER"
"NCRNAS INVOLVED IN WNT SIGNALING IN HEPATOCELLULAR CARCINOMA","1","0.67665528504595",NA,"2.08","60632","INCREASE HERITABLE MUTATIONS IN OFFSPRING"
"INCREASED SUSCEPTIBILITY TO FRACTURES","1","0.67665528504595",NA,"2.86","60632","INCREASED DISEASE SUSCEPTIBILITY"
